Mitral Regurgitation (MR)SK M-CLIPNCT07045753
The Prospective Segeberg Registry for Mitral Transcatheter Edge-to-Edge Repair
An observational study of Mitral Regurgitation (MR), run by Segeberger Kliniken GmbH at 1 site in Germany.
Trial summary
A Prospective Follow-up Assessment in Bad Segeberg for Patients with severe MR undergoing M-TEER Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Mitral Regurgitation (MR)
- What is being tested?
- Transcatheter edge to edge repair
- Type of treatment
- Medical device
- How many people
- 2,000 participants
- Where
- 1 siteGermany
- Study dates
- 1 Jan 2011to 31 Dec 2032
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with severe MR undergoing M-TEER
Who may be able to join
- Patients with severe MR undergoing M-TEER
Who cannot join
- None
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Stephan Fichtlscherer, Prof., MD contact
Germany1 site, 1 recruiting
- Recruiting
Herzzentrum Segeberger Kliniken GmbH
Bad Segeberg, Schleswig-Holstein, 23795
Holger Nef, Prof., MD, +4945512802 ext. 9890, holger.nef@me.com
About this study
Official title: A Prospective Follow-up Assessment in Bad Segeberg With Patients With Severe Mitral Regurgitation Undergoing Mitral Edge-to-edge Repair (M-TEER).
A Prospective Follow-up Assessment in Bad Segeberg for Patients with severe MR undergoing M-TEER
Read the detailed description
A prospective single center registry including all patients treated for severe mitral regurgitation (MR) with mitral edge-to-edge repair (M-TEER) at the Heart Center, Bad Segeberg, Germany. Patients undergo a routine clinical follow-up schedule, including a long-term follow-up.
- Conditions
- Mitral Regurgitation (MR)
- Being tested
- Transcatheter edge to edge repair
- Keywords
- M TEER, Mitral Clip
- Medical subject headings
- Mitral Valve Insufficiency
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Transcatheter edge to edge repairDevice
Also called M TEER, Mitral Clip
mitral valve transcatheter edge-to-edge repair
| Study group | Role | What they receive |
|---|---|---|
| Patients of severe MR undergoing M-TEER | Patients with severe mitral regurgitation undergoing transcatheter edge to edge repair (M-TEER) Receives: Device: Transcatheter edge to edge repair |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of in-hospital and long-term cardiovascular adverse events in percent
Peri-procedural events and in-hospital cardiovascular events and long-term cardiovascular events (bleeding, peripheral and coronary vascular complication, stroke, myocardial infarction, stent thrombosis, revascularization, death, heart failure, rehospitalization)
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jul 2025
- Study start1 Jan 2011
- Primary completion31 Dec 2030 (estimated)
- Study completion31 Dec 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Mitral Regurgitation (MR)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Segeberger Kliniken GmbH
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Holger Nef, Prof., MD, Study director, Herzzentrum Segeberger Kliniken GmbH
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07045753
- Sponsor's protocol ID
- SK 113 - 168/11
- Acronym
- SK M-CLIP
- Status last verified
- Jun 2025
- First submitted
- 22 Jun 2025
- Last updated
- 1 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Follow-up Assessment in Bad Segeberg With Patients With Severe Mitral Regurgitation Undergoing Mitral Edge-to-edge Repair (M-TEER).
- ClinicalTrials.gov ID
- NCT07045753
- Acronym / sponsor ID
- SK M-CLIP / SK 113 - 168/11
- Conditions
- Mitral Regurgitation (MR)
- Keywords
- M TEER, Mitral Clip
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 2,000 participants (estimated)
- Lead sponsor
- Segeberger Kliniken GmbHUniversity, hospital or other
- Study start
- 1 Jan 2011 (actual)
- Primary completion
- 31 Dec 2030 (estimated)
- Study completion
- 31 Dec 2032 (estimated)
- First posted
- 1 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A Prospective Follow-up Assessment in Bad Segeberg for Patients with severe MR undergoing M-TEER
Detailed description
A prospective single center registry including all patients treated for severe mitral regurgitation (MR) with mitral edge-to-edge repair (M-TEER) at the Heart Center, Bad Segeberg, Germany. Patients undergo a routine clinical follow-up schedule, including a long-term follow-up.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients of severe MR undergoing M-TEER | – | Device: Transcatheter edge to edge repairPatients with severe mitral regurgitation undergoing transcatheter edge to edge repair (M-TEER) |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with severe MR undergoing M-TEER
Key inclusion criteria (1 listed)
- Patients with severe MR undergoing M-TEER
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Transcatheter edge to edge repairAlso: M TEER, Mitral Clipmitral valve transcatheter edge-to-edge repair | Device | Patients of severe MR undergoing M-TEER |
Primary outcome
Rate of in-hospital and long-term cardiovascular adverse events in percent
Time frame: 2 years
Peri-procedural events and in-hospital cardiovascular events and long-term cardiovascular events (bleeding, peripheral and coronary vascular complication, stroke, myocardial infarction, stent thrombosis, revascularization, death, heart failure, rehospitalization)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jul 2025.
- Individual participant dataSharing planned: No
Related trials for Mitral Regurgitation (MR)
Not yet recruiting
Early Feasibility Study of the Capstan Medical TMVR System
Mitral Regurgitation (MR)
Not yet recruiting
Early Feasibility Study of NeoChord Transcatheter Mitral Repair System
Degenerative Mitral Regurgitation, Degenerative Mitral Regurgitation (MR) Due to Leaflet Prolapse
Active, not recruiting
Use of Force Feedback Instruments With the da Vinci Surgical System, Model IS5000 for Mitral Valve Repair
Mitral Regurgitation (MR)
Recruiting
PRECISE-AFMR I: Transcatheter Mitral Valve Edge-to-Edge Repair for Atrial Functional Mitral Regurgitation in Patients at High Surgical Risk
Atrial Functional, Mitral Regurgitation (MR)
RecruitingObservational study
Examination of Nociscan Impact on Low Back Pain Surgical Outcomes
Low Back Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Stephan Fichtlscherer, Prof., MD contact
Holger Nef, Prof., MD study director
Herzzentrum Segeberger Kliniken GmbH
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Mitral Regurgitation (MR), run by Segeberger Kliniken GmbH at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 1 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Arief Kurniadi, MD (+4945512802 ext. 9293, arief.kurniadi@segebergerkliniken.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of in-hospital and long-term cardiovascular adverse events in percent (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jul 2025.